Novo Nordisk has just announced the results of the CAPTURE study, a non-interventional study worldwide to find out the prevalence of cardiovascular diseases, risks and their management in people with type 2 diabetes.
The study, the first of its kind and involving nearly 10,000 participants from 13 countries on five continents, showed that 1 in 3 people with type 2 diabetes has established cardiovascular disease, 9 out of 10 with atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular disease is caused by the accumulation of fats, cholesterol and other substances in the walls of the arteries, narrowing the vessels and decreasing blood flow, which can potentially lead to episodes such as a myocardial infarction or stroke. The CAPTURE study also highlighted that only 2 out of 10 people with type 2 diabetes and atherosclerotic cardiovascular disease are receiving glucose-lowering treatment with proven cardiovascular benefits.
“The findings of the CAPTURE study are significant for anyone involved in the care of people with type 2 diabetes. The data reveal that, although the prevalence of atherosclerotic cardiovascular disease in the population with type 2 diabetes is high, the vast majority are not receive treatments that have been proven to reduce the risk of potentially serious cardiovascular episodes, ”says investigator Dr. Ofri Mosenzon, consultant for Novo Nordisk and the Diabetes Unit at Hadassah Medical Center in Israel. “It is critical that we prioritize cardiovascular disease as key factors in the management of type 2 diabetes.”
People with type 2 diabetes need to be more aware of their risk factors and doctors need to be active in tracking them. Nowadays, it is possible to control this risk through treatments with proven cardiovascular benefits, as recommended in several treatment guidelines ”.
For the first time, information was collected on cardiovascular diseases in type 2 diabetes in the context of primary and hospital healthcare, which also demonstrates that a significant proportion of people with type 2 diabetes are being followed up in general and family medicine together with diabetes experts.
“Cardiovascular disease is the leading cause of disability and death among people with type 2 diabetes. Until recently, the link between type 2 diabetes and cardiovascular disease was not fully valued on a global scale,” says Stephen Gough, medical director at Novo Nordisk. “Through our continuous investment, including the CAPTURE study, Novo Nordisk hopes that, with a greater understanding of the disease and its management, healthcare professionals will gain more knowledge about the most appropriate way to control this disease and improve the results of sick. ”